Acurx's Ibezapolstat Shows Promising Mechanism Against Gram-Positive Bacteria

Event summary

  • Acurx presented structural biology findings on ibezapolstat at the LED3 conference on June 11, 2026.
  • High-resolution cryo-electron microscopy resolved ibezapolstat's binding to Gram-positive DNA pol IIIC at 3.2Å.
  • The active site of the polymerase is conserved in over 220 Gram-positive species, suggesting broad clinical utility.
  • Ibezapolstat has received FDA QIDP and Fast-Track designations, along with EMA SME designation.
  • Acurx plans to commence international Phase 3 trials for ibezapolstat in treating C. difficile infection.

The big picture

Acurx's findings underscore the growing need for novel antibiotics targeting Gram-positive bacteria, particularly as antimicrobial resistance continues to rise. The company's strategic focus on maintaining a healthy gut microbiome sets it apart in the competitive landscape of infectious disease treatments. With positive regulatory guidance from both the FDA and EMA, Acurx is well-positioned to advance its lead candidate, ibezapolstat, through pivotal trials and potentially address a significant unmet medical need in C. difficile infections.

What we're watching

Clinical Trial Progress
The pace at which Acurx advances ibezapolstat through Phase 3 trials will determine its market potential.
Regulatory Pathway
Whether Acurx can secure both FDA and EMA approvals will be critical for global commercialization.
Pipeline Expansion
How Acurx leverages structural insights to develop additional antibiotics for Gram-positive infections.